• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Inotiv Inc.

    7/20/26 8:04:33 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NOTV alert in real time by email
    S-8 POS 1 tm2620691d7_s8pos.htm S-8 POS

      

    As filed with the Securities and Exchange Commission on July 20, 2026

    Registration No. 333-285784

    Registration No. 333-279732

    Registration No. 333-261025

    Registration No. 333-237580

    Registration No. 333-228747

    Registration No. 333-153734

    Registration No. 333-261038

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-285784

    POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-279732

    POST-EFFECTIVE AMENDMENT NO. 2 FORM S-8 REGISTRATION STATEMENT NO. 333-261025

    POST-EFFECTIVE AMENDMENT NO. 2 FORM S-8 REGISTRATION STATEMENT NO. 333-237580

    POST-EFFECTIVE AMENDMENT NO. 2 FORM S-8 REGISTRATION STATEMENT NO. 333-228747

    POST-EFFECTIVE AMENDMENT NO. 2 FORM S-8 REGISTRATION STATEMENT NO. 333-153734

    POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-261038

      

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Inotiv, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

      

    Indiana

    (State or other jurisdiction of

    incorporation or organization)

     

    35-1345024

    (I.R.S. Employer Identification No.)

     

    2701 Kent Avenue

    West Lafayette, Indiana 47906-1382

    (Address of principal executive offices) (Zip Code)

     

    Inotiv, Inc. 2024 Equity Incentive Plan

    Amended and Restated Inotiv, Inc. 2018 Equity Incentive Plan

    Amended and Restated Bioanalytical Systems, Inc. 2018 Equity Incentive Plan

    2008 Stock Option Plan as Amended and Restated in the form of the

    Amended and Restated Bioanalytical Systems, Inc. Equity Incentive Plan

    Certain Stock Option Agreements and 2008 Stock Option Plan

    Envigo RMS Holding Corp. Equity Incentive Plan

    (Full titles of the plans)

     

     

    Copy to: 

       

    Beth A. Taylor

    Chief Financial Officer

    Inotiv, Inc.

    2701 Kent Avenue

    West Lafayette, Indiana 47906-1382

    (765) 463-4527

    (Name, address and telephone number

    including area code, of agent for service) 

    Christine G. Long

    Griffin D. Foster

    Faegre Drinker Biddle & Reath LLP

    600 E. 96th Street, Suite 600

    Indianapolis, Indiana 46240

    (317) 569-9600

      

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer  x
       
    Non-accelerated filer   ¨ Smaller reporting company  ¨
       
     

    Emerging growth company ¨

      

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

      

     

     

     

     

      

    DEREGISTRATION OF SECURITIES 

     

    These Post-Effective Amendments (these “Post-Effective Amendments”) are being filed by Inotiv, Inc. (the “Registrant”) to deregister all securities registered under the following Registration Statements on Form S-8 (the “Registration Statements”) filed by the Registrant with the U.S. Securities and Exchange Commission (the “Commission”), each as amended or supplemented to date, that remain unsold as of the date hereof:

     

    1.       Registration Statement No. 333-285784, registering an additional 2,250,000 common shares, no par value per share (the “Common Shares”), of the Registrant reserved for issuance under the Inotiv, Inc. 2024 Equity Incentive Plan, as amended March 13, 2025, which was filed with the Commission on March 13, 2025;

     

    2. Registration Statement No. 333-279732, registering an aggregate of 1,500,000 Common Shares issuable under the Inotiv, Inc. 2024 Equity Incentive Plan, which was filed with the Commission on May 24, 2024;

     

    3. Registration Statement No. 333-261025, registering an aggregate of 1,500,000 Common Shares issuable under the Amended and Restated Inotiv, Inc. 2018 Equity Incentive Plan, which was filed with the Commission on November 12, 2021, as amended May 24, 2024;

     

    4.       Registration Statement No. 333-237580, registering an aggregate of 700,000 Common Shares issuable under the Amended and Restated Bioanalytical Systems, Inc. 2018 Equity Incentive Plan, which was filed with the Commission on April 6, 2020, as amended May 24, 2024;

     

    5.       Registration Statement No. 333-228747, registering an aggregate of 700,000 Common Shares issuable under the 2008 Stock Option Plan as Amended and Restated in the form of the Amended and Restated Bioanalytical Systems, Inc. 2018 Equity Incentive Plan, which was filed with the Commission on December 11, 2018, as amended May 24, 2024;

     

    6.       Registration Statement No. 333-153734, registering an aggregate of 958,000 Common Shares issuable under certain Stock Option Agreements and the 2008 Stock Option Plan, which was filed with the Commission on September 30, 2008, as amended May 24, 2024; and

     

    7.       Registration Statement No. 333-261038, registering an aggregate of 790,620 Common Shares issuable under the Envigo RMS Holding Corp. Equity Incentive Plan, which was filed with the Commission on November 12, 2021.

     

    As previously disclosed, on June 3, 2026, the Registrant and certain of its direct and indirect subsidiaries filed voluntary petitions commencing cases under Chapter 11 of Title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the “Court”) to implement a prepackaged chapter 11 plan of reorganization (as amended, modified or supplemented from time to time, the “Plan”). On July 14, 2026, the Court entered an order (the “Confirmation Order”) confirming the Plan, as modified by the Confirmation Order, and on July 17, 2026, the Plan became effective in accordance with its terms and the Registrant emerged from bankruptcy, and in connection therewith, all Common Shares and other equity interests in the Registrant were cancelled and terminated. Accordingly, the Registrant has terminated all offerings of securities pursuant to the Registration Statements.

     

    In accordance with the undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that remain unsold at the termination of the offering, the Registrant hereby removes from registration all securities that were registered under each of the Registration Statements but remain unsold as of the date hereof. As of the date hereof, the Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of each of the Registration Statements.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of West Lafayette, Indiana, on July 20, 2026.

     

    INOTIV, INC.

     

    By:   /s/ Beth A. Taylor  
        Name: Beth A. Taylor  
        Title: Chief Financial Officer  

     

    Pursuant to Rule 478 under the Securities Act of 1933, no other person is required to sign these Post-Effective Amendments. 

     

     

    Get the next $NOTV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NOTV

    DatePrice TargetRatingAnalyst
    5/14/2024$11.50 → $3.75Buy → Hold
    Jefferies
    2/9/2024$3.00 → $11.50Hold → Buy
    Jefferies
    7/20/2023$9.00Overweight
    Wells Fargo
    1/19/2023$10.00 → $8.00Buy → Hold
    Jefferies
    1/11/2023$4.00 → $10.00Hold → Buy
    Lake Street
    11/18/2022$60.00 → $7.00Buy → Hold
    Lake Street
    10/4/2022$27.00Buy
    Jefferies
    1/31/2022$60.00Buy
    Lake Street
    More analyst ratings

    $NOTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inotiv Successfully Completes Financial Restructuring Process

    Emerges from Chapter 11 with a stronger balance sheet, well positioned to execute on its long-term growth initiatives Key senior management continue to lead Inotiv; team remains focused on providing clients with critical research products and services Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today the completion of its financial restructuring process and emergence from Chapter 11 protection. Through the restructuring process, Inotiv has reduced its debt by approximately $326 million

    7/20/26 4:26:00 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv Announces Confirmation of Plan of Reorganization

    Marks critical milestone in financial restructuring process, positioning Inotiv to emerge well-capitalized, with an improved balance sheet and support from key stakeholders Company is poised to execute on long-term growth objectives Operations continue as usual, including ongoing study execution and partner engagement Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that the U.S. Bankruptcy Court for the Southern District of Texas has confirmed the Company’s Plan of Reorganization (the

    7/14/26 6:26:00 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth

    Receives commitments for $65 million in new money financing to support ongoing business operations Recapitalization effectuated through a pre-packaged plan of reorganization on an expedited basis Transaction is supported by substantially all of the Company's existing lenders Normal business operations will continue seamlessly with no impact on vendors and suppliers Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it has entered into a Restructuring Support Agreement ("RSA") with

    6/3/26 6:15:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Inotiv downgraded by Jefferies with a new price target

    Jefferies downgraded Inotiv from Buy to Hold and set a new price target of $3.75 from $11.50 previously

    5/14/24 8:01:45 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv upgraded by Jefferies with a new price target

    Jefferies upgraded Inotiv from Hold to Buy and set a new price target of $11.50 from $3.00 previously

    2/9/24 6:17:55 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Wells Fargo initiated coverage on Inotiv with a new price target

    Wells Fargo initiated coverage of Inotiv with a rating of Overweight and set a new price target of $9.00

    7/20/23 7:55:03 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Brown Nigel disposed of 104,929 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    7/20/26 4:39:37 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Financial Officer Taylor Beth A. disposed of 139,616 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    7/20/26 4:38:18 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Strategy Officer Sagartz John E disposed of 729,626 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    7/20/26 4:36:50 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    SEC Filings

    View All

    SEC Form S-8 POS filed by Inotiv Inc.

    S-8 POS - Inotiv, Inc. (0000720154) (Filer)

    7/20/26 8:06:12 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form S-8 POS filed by Inotiv Inc.

    S-8 POS - Inotiv, Inc. (0000720154) (Filer)

    7/20/26 8:05:51 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form S-8 POS filed by Inotiv Inc.

    S-8 POS - Inotiv, Inc. (0000720154) (Filer)

    7/20/26 8:05:19 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Landman David bought $99,998 worth of shares (23,529 units at $4.25), increasing direct ownership by 15% to 176,851 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    12/23/24 9:47:13 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Operating Officer Beattie John Gregory bought $142,500 worth of shares (30,000 units at $4.75), increasing direct ownership by 23% to 161,761 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    12/12/24 6:46:46 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Brown Nigel bought $31,950 worth of shares (7,500 units at $4.26), increasing direct ownership by 13% to 65,537 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    12/10/24 4:13:30 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Leadership Updates

    Live Leadership Updates

    View All

    Universal Display Corporation Announces the Appointment of New Board Members

    Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

    3/7/24 4:05:00 PM ET
    $BDN
    $NOTV
    $OLED
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv, Inc. Announces Changes to its Board Composition

    WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board's succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board. Ms. Coelho is the CFO at Gamida Cell Ltd., a public, commercial stage biotech company. Previously, Ms. Coelho was Executive Vice President, CFO and Chief Business Development Offic

    10/16/23 8:00:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Financials

    Live finance-specific insights

    View All

    Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update

    –   First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million –   First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million –   Conference call scheduled for today at 8:30 am ET  WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2026") ended December 31, 2025. Revenue by Segment (in millions of USD)  Three Months Ende

    2/9/26 7:00:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026

    WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2026 first quarter ended December 31, 2025, on Monday, February 9, 2026, before the stock market opens. The Company will host a conference call that same day at 8:30 a.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-445-7795 (Domestic)1-785-424-1699 (International)INOTIV (Co

    2/4/26 6:30:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update

    –  Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million–  Fiscal 2025 revenue increased 4.5% to $513.0 million–  Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million–  Fiscal 2025 operating loss decreased 64.2% to $30.9 million–  Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q4 FY 2025") ended September 30, 2025, and twelve mo

    12/3/25 4:05:00 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

    SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

    4/3/24 10:47:10 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

    SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

    10/6/22 12:24:15 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

    SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

    9/20/22 9:00:08 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care